Answers are grounded in this paper and cite their sources.
Background and objectives To define the expansive and atypical clinical spectrum and molecular basis of a mitochondrial disease in a Chinese pedigree, with particular attention to multisystem involvement, and to characterize the functional consequences of an SDHA variant. Methods Seven family members underwent clinical phenotyping. The proband (IV-1) underwent detailed clinical, electrophysiologic, and neuroimaging evaluation. Whole-exome sequencing and mitochondrial genome sequencing were performed in the proband, and Sanger sequencing was used in available relatives (III-1, III-2, and IV-2) for variant validation and cosegregation analysis. The variant was further evaluated by protein structure prediction and Gaussian network model. Transcriptome analysis and enzyme activity assays were performed in the proband and her father (III-1). Results The proband, a 24-year-old woman, developed an acute febrile illness followed by headache, neck stiffness, vomiting, limb weakness, diplopia, blurred vision, ataxia, diabetes insipidus, mixed ventilatory dysfunction, cognitive impairment, seizures, tremor, esophageal spasm, abdominal pain, sinus arrest, and hypotension. Serial MRI of the entire neuraxis was unrevealing. Repeated CSF examinations consistently showed normal WBC count, glucose, and protein levels, despite a single episode of elevated intracranial pressure reaching 280 mmH2O. She was diagnosed with mitochondrial disease and improved markedly after 2 years of mitochondrial cocktail therapy. Her father and another relative (III-2) had similar but substantially milder manifestations that had previously gone unrecognized. Genetic analysis identified a heterozygous SDHA variant, NM_004168.4:c.596C > T (p.Ser199Leu), in the three genotyped affected members (IV-1, III-1, III-2). In the proband and her father, transcriptome analysis confirmed the SDHA variant but detected no aberrant transcripts or gene fusions, and enzyme assays suggested decreased succinate dehydrogenase activity in peripheral blood mononuclear cells. Ser199 resides within the flavin adenine dinucleotide (FAD)-binding domain. Compared with the wild-type structure, the modelled p.Ser199Leu structure displayed higher potential energy and greater global and local flexibility at the FAD-binding domain and FAD-binding site, predicting reduced domain stability and a potential impact on FAD binding and electron transfer. Conclusions This pedigree extends the clinical spectrum of SDHA -related mitochondrial disease and demonstrates marked intrafamilial variability. SDHA variants may present as an acute, MRI-negative multisystem disorder involving the central nervous system, autonomic, endocrine, respiratory, and cardiac conduction systems. Integrated clinical, transcriptomic, enzymatic, and structural findings are consistent with a possible functional effect of p.Ser199Leu and suggest a mechanism involving destabilization of the FAD-binding domain. However, due to insufficient evidence to establish pathogenicity, this variant is currently classified as a variant of uncertain significance, pending further functional data.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: